# Artiva Biotherapeutics, Inc.: filings

ARTV · Nasdaq · CIK 1817241 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/artv.md) · [Financials](/companies/artv/financials.md) · [Filings](/companies/artv/filings.md) · [Insiders](/companies/artv/insiders.md)

## Reports and events: 48 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 99, 3 22, 8-K 22, 144 13, 10-Q 7, CORRESP 5, S-1/A 5, S-8 4, SCHEDULE 13D/A 4, EFFECT 3, SC 13G 3, SCHEDULE 13G/A 3, UPLOAD 3, 10-K 2, ARS 2, D 2, DEF 14A 2, DRS 2, S-1 2, S-3 2, SC 13D 2, SEC STAFF LETTER 2, 10-K/A 1, 424B4 1, 424B5 1, 4/A 1, 8-A12B 1, CERT 1, DEFA14A 1, DRS/A 1, DRSLTR 1, FWP 1, RW 1, S-1MEF 1, SC 13D/A 1, SC 13G/A 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 08:30 ET | [8-K](/filings/0001193125-26-432806.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0001193125-26-432806 |
| 2026-09-11 | 16:21 ET | [8-K](/filings/0001193125-26-389308.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-389308 |
| 2026-08-06 | 16:12 ET | [10-Q](/filings/0001193125-26-338029.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338029 |
| 2026-08-06 | 16:09 ET | [8-K](/filings/0001193125-26-337986.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337986 |
| 2026-08-03 | 16:08 ET | [DEF 14A](/filings/0001193125-26-330563.md) | Proxy statement, period 2026-09-08 | 0001193125-26-330563 |
| 2026-07-23 | 21:23 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000203.md) | Ownership report, active investor, amended | 0001346824-26-000203 |
| 2026-07-22 | 17:15 ET | [8-K](/filings/0001193125-26-312560.md) | 8.01 Other events | 0001193125-26-312560 |
| 2026-06-15 | 19:37 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000173.md) | Ownership report, active investor, amended | 0001346824-26-000173 |
| 2026-05-28 | 16:38 ET | [SCHEDULE 13D/A](/filings/0001931382-26-000009.md) | Ownership report, active investor, amended | 0001931382-26-000009 |
| 2026-05-19 | 08:07 ET | [8-K](/filings/0001193125-26-229714.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-229714 |
| 2026-05-13 | 17:47 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000129.md) | Ownership report, active investor, amended | 0001346824-26-000129 |
| 2026-05-08 | 16:24 ET | [8-K](/filings/0001193125-26-214711.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-214711 |
| 2026-05-08 | 06:40 ET | [10-Q](/filings/0001193125-26-213242.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213242 |
| 2026-05-08 | 06:37 ET | [8-K](/filings/0001193125-26-213239.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-213239 |
| 2026-04-30 | 16:01 ET | [10-K/A](/filings/0001193125-26-197115.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-197115 |
| 2026-03-10 | 16:09 ET | [10-K](/filings/0001193125-26-100135.md) | Annual report, period 2025-12-31 | 0001193125-26-100135 |
| 2026-03-10 | 16:07 ET | [8-K](/filings/0001193125-26-100131.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-100131 |
| 2026-02-24 | 17:14 ET | [8-K](/filings/0001193125-26-067509.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-067509 |
| 2026-02-19 | 17:20 ET | [8-K](/filings/0001193125-26-059716.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-059716 |
| 2025-12-12 | 17:23 ET | [8-K](/filings/0001193125-25-317784.md) | 5.02 Departure or appointment of officers or directors | 0001193125-25-317784 |
| 2025-11-12 | 07:22 ET | [8-K](/filings/0001193125-25-275902.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-275902 |
| 2025-11-12 | 07:08 ET | [10-Q](/filings/0001193125-25-275872.md) | Quarterly report, period 2025-09-30 | 0001193125-25-275872 |
| 2025-11-12 | 07:05 ET | [8-K](/filings/0001193125-25-275867.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-275867 |
| 2025-08-06 | 16:13 ET | [10-Q](/filings/0000950170-25-104045.md) | Quarterly report, period 2025-06-30 | 0000950170-25-104045 |
| 2025-08-06 | 16:11 ET | [8-K](/filings/0000950170-25-104028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104028 |
| 2025-06-25 | 16:02 ET | [8-K](/filings/0000950170-25-089942.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-089942 |
| 2025-05-08 | 08:06 ET | [10-Q](/filings/0000950170-25-066421.md) | Quarterly report, period 2025-03-31 | 0000950170-25-066421 |
| 2025-05-08 | 08:03 ET | [8-K](/filings/0000950170-25-066416.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066416 |
| 2025-04-29 | 21:34 ET | [DEF 14A](/filings/0001193125-25-101364.md) | Proxy statement, period 2025-06-24 | 0001193125-25-101364 |
| 2025-03-24 | 16:09 ET | [10-K](/filings/0000950170-25-043837.md) | Annual report, period 2024-12-31 | 0000950170-25-043837 |
| 2025-03-24 | 16:07 ET | [8-K](/filings/0000950170-25-043828.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-043828 |
| 2025-01-29 | 16:07 ET | [8-K](/filings/0000950170-25-010481.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-010481 |
| 2024-11-12 | 16:10 ET | [10-Q](/filings/0000950170-24-125382.md) | Quarterly report, period 2024-09-30 | 0000950170-24-125382 |
| 2024-11-12 | 16:07 ET | [8-K](/filings/0000950170-24-125359.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125359 |
| 2024-10-22 | 16:13 ET | [8-K](/filings/0001193125-24-241059.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-241059 |
| 2024-09-03 | 16:18 ET | [SC 13D/A](/filings/0001104659-24-096378.md) | Ownership report, active investor, amended | 0001104659-24-096378 |
| 2024-08-29 | 16:18 ET | [10-Q](/filings/0001193125-24-209924.md) | Quarterly report, period 2024-06-30 | 0001193125-24-209924 |
| 2024-08-29 | 16:16 ET | [8-K](/filings/0001193125-24-209920.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-209920 |
| 2024-07-29 | 16:29 ET | [SC 13D](/filings/0001104659-24-083555.md) | Ownership report, active investor | 0001104659-24-083555 |
| 2024-07-29 | 16:15 ET | [SC 13D](/filings/0001193125-24-187576.md) | Ownership report, active investor | 0001193125-24-187576 |
| 2024-07-22 | 16:19 ET | [8-K](/filings/0001193125-24-182231.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-182231 |
| 2024-07-15 | 06:07 ET | [S-1/A](/filings/0001193125-24-178806.md) | Registration statement, amended | 0001193125-24-178806 |
| 2024-06-28 | 16:04 ET | [S-1](/filings/0001193125-24-172230.md) | Registration statement | 0001193125-24-172230 |
| 2022-06-06 | 17:29 ET | [S-1/A](/filings/0001193125-22-168492.md) | Registration statement, amended | 0001193125-22-168492 |
| 2022-03-07 | 16:28 ET | [S-1/A](/filings/0001193125-22-068001.md) | Registration statement, amended | 0001193125-22-068001 |
| 2022-01-21 | 17:29 ET | [S-1/A](/filings/0001193125-22-014926.md) | Registration statement, amended | 0001193125-22-014926 |
| 2021-12-16 | 21:49 ET | [S-1/A](/filings/0001193125-21-358277.md) | Registration statement, amended | 0001193125-21-358277 |
| 2021-04-08 | 17:16 ET | [S-1](/filings/0001193125-21-110347.md) | Registration statement | 0001193125-21-110347 |

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 08:31 ET. No prices; not investment advice.